Thank and everyone. you, hello, Erik,
X. Slide to Moving
with providing credit-adjusted our reduced this the IFF's to competitive management up committed value opportunity to and dividend actions our we long important consistent is towards payouts. dividend our new we part as returns to to allocation with have more base share. we believe $X.XX term. debt- of improvement for set remains Erik in and accelerate to quarterly long-term and framework, expect Xx that dividend taken change yield Consequently, us profit of generation durable that the per industry an provides aligned believes a work this our IFF Board is and deleveraging target the our our grow As creation We cash target and capital have structure The these of flow shareholders to mentioned, time. capital dividend EBITDA. peers net this over alongside remains firmly
Now, Slide X. on
growth volume mentioned, the for implemented IFF both in continued increase sales, performance our our business team Scent growth several in the environment. has months challenges to trends improve by Pharma, increases destocking. uncertain the reflected for last Despite sequentially impacted and over that improvement and businesses nearly resulting quarter strong fourth volume amid in initiatives operational in reflects operating sales. a to in some Erik currency-neutral strategic continued our As an the market, Nourish in $X.X in strong X% IFF. representing deliver results This generated with billion total all pressure with continued comparable
to would XX% in for functional sequentially impact currency-neutral low mid-single digits. the the improve Volumes single quarter ingredients, digits on comparable from a single QX and down in fourth fourth operating low of to digits in increase $XXX volumes continue have down excluding the quarter, if a Adjusted QX, basis. increased million totaled EBITDA
net efficiencies both We in also margin. basis from realized This XXX taken, currency-neutral favorable including gains initiatives and a operating supported year-over-year continued was comparable has increase of growth adjusted steps pricing. productivity our IFF and internal by our points EBITDA approximately EBITDA to
The the ingredients, to the are a billion our mainly lower that I fourth Nourish exchange to impairment related fluctuations. cost inflation rate impairment business. drivers due we business unfavorable on, related goodwill to primary and in of share moving wanted quarter goodwill projections recorded volume noncash Before functional of for declines to charge foreign $X.X continued
XX%. to at growth closer helped our to a us to moving net adjusted look Slide delivered robust we a with productivity strong deliver overcome fourth quarter, EBITDA realized to profitability our which inflation happy X. to equates Taking and report million, IFF in of ongoing QX, Now volume currency-neutral for I'm the conjunction price against operating comparable performance objectives. that in $XXX favorable gains pressures
executing upon these to investments Importantly, IFF remained our while and effectiveness making to programs areas. also improve growth continued productivity operational part launch XXXX, as steps focused has of in efficiency. program In additional we strategic our key on
strong segment our in continued in the a was by business quarter. performance a on declined Nourish, during functional as look XX, offset X% by In Now I'll basis softness Slide growth sales on ingredients. comparable currency-neutral provide at Flavors closer
remains of is driver meaningful operating profitability, and for worth and positive impact the weakness that our a led in actions Nourish productivity improvements terms quarter, again in While it we the functional from EBITDA. main X% pricing to increase saw adjusted noting the currency-neutral comparable ongoing sequential of ingredients improvement drove a initiatives in
in increases, of and bottom Overall, comparable year-over-year in H&B top and by EBITDA. robust growth. led Price H&B year-over-year currency-neutral XX% increase a operating growth gains increase show line across sales most to to and continue Health. comparable double-digit growth growth X% led business productivity volume segments currency-neutral a Biosciences adjusted delivered & Health
in favorable including productivity continued also XX% significant performance currency-neutral Our in XX% a comparable as Fragrance on currency-neutral pricing, and driven driven Biosciences, very deliver double-digit mid-single-digit growth & Health strong QX, growth net a comparable EBITDA, growth Fragrance. in to adjusted Like growth in Scent as Consumer increasing saw sales well operating Fine gains. Scent segment in by volume basis, by
by year ago continued sales XX% adjusted While Pharma EBITDA driven Solutions the declined as XX% primarily productivity destocking currency-neutral lower declining currency-neutral quarter. strong gains, pricing to improvements volume, comparable were comparison. and led these as and by offset experienced trends significant well comparable operating This in
positions. I'll totaled In XX. strong the sales. operations Slide fourth year, improving CapEx our discuss progress the reflecting billion, leverage the in million $XXX to X.X% was previous quarter, cash significant flow the or inventory levels. $X.XX for of from and year approximately cash a Turning increase from flow our improvement
$XXX $XXX on cash the of on helped which of working our our progress and capital intense rightsizing totaling by over an a ahead free year position, for expectations. increase saw million, sequential inventories enhance Our improvement, full led flow million focus
flow transaction-related primarily in and integration free Included items. million cash $XXX related of is about our to cost,
to $XXX in XXXX. million We delivered also in our dividends shareholders
QX. million, Our cash equivalents assets and sale $XX for $XXX totaled in held in million including cash
billion quarter Additionally, of a debt, $XX.X million we credit with the in for EBITDA debt totaled to realized adjusted gross which net a approximately sequential $XXX X.Xx. reduction
credit $X.X Our EBITDA adjusted approximately trailing XX-month totaled billion.
leverage Lucas announced our achieve targets. are which we the actions expect rightsizing additional Meyer Cosmetics our the of quarterly of dividend and and to in portfolio to balance are make, still decisive XXXX, we business, quarter our planning sale of action With taking to strengthen close first we sheet the our
our broader XX, now the end to improvements ahead. tail are of we market a On business across cautiously turn and in combination towards like Slide our I'd 'XX. Due of outlook 'XX, about for to optimistic to the the year
ingredients range the This such is given which lower 'XX, year impact largely reflects full fragrance $XX.X to our dynamics. of in of categories price-competitive and the and approach pricing to expectations billion costs isolated to prudent XXXX, in functional expect input competitive For the volume sales $XX.X negative we billion. ingredients modest as and more
pricing cost-competitive position believe increase expect to X.X% market us decline 'XX, a We approximately a in this X% increase following in in us Strategically, regain be overall more select will to XX% and 'XX in market to the in businesses. and allow share we 'XX.
of volume, pace range significant will fluid incorporated most a variable X% has In impacting and to visibility the be range. ingredients. our X% the degree the pace functional in recovery in terms of this The remains explicitly of the been bit to recovery and in
industry low this to from 'XX, believe growth down were normalized more and we our we down return However, digits a finished 'XX, as single marked improvement is mid-single where rates. we digits will
$X.X billion deliver between bottom year operating and expect we full to the line, 'XX On billion. EBITDA $X.X adjusted
volumes improved just not and expansion but segments. margin solid a assumes guidance our 'XX, profitability from across also Our
businesses. hyper-focused to to continuing while expected continuing productivity inflation, help reinvest and in labor initiatives to execute return compensation incentive mitigate the our on costs, We higher reset, are primarily
benefit Kernel of that program LBK, this inventory expense million approximately noting 'XX we 'XX. negative in estimated onetime as some Locust in It's declines, will we repeat we compensation quarter. $XXX 'XX as $XXX Bean inventory from by to of third an program is and items the in provided reset the related announced target impact absorption the which related levels our write-down in will there not volume million also worth incentive annual XXXX. A reduction impact In negative particular, previously have an be in such down from was to reduction higher offset from and the of some to inventory or payout portion our
all profitability the X work to still efforts effective, the market divisions. portfolio see improvement divisions it's across hard bolster expansion financial of predict and impact opportunity and for all providing in targeting are to and timing in While margin its while results, 'XX to our volumes improvements on with and and profile better details we our with there's recovery do,
For the $XXX first quarter, to approximately an of be approximately million. $XXX billion $X.X million adjusted billion, sales to we expect EBITDA $X.X to with
to portfolio, focused improve will reach our Throughout and financial optimize efforts relentlessly be performance deleveraging on XXXX, we targets. our our
actions our the and to significant will in 'XX performance 'XX value I'm improving capture confident IFF position creation. that taken outlook for in
With turn call back that, remarks. over the closing I'll Erik for to